Document is current

Documents that mention this clinical trial

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246

296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0296

Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019

Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
https://doi.org/10.1136/jitc-2021-002998

540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2021-sitc2021.540

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
https://doi.org/10.1136/annrheumdis-2018-213777

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
https://doi.org/10.1136/jitc-2020-001064

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552

Documents that mention this clinical trial

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404

296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0296

Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019

Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
https://doi.org/10.1136/jitc-2021-002998

540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2021-sitc2021.540

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
https://doi.org/10.1136/annrheumdis-2018-213777

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
https://doi.org/10.1136/jitc-2020-001064

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552